EGFR and non-small cell lung carcinoma: Osimertinib, a novel mutant-selective irreversible third-generation EGFR tyrosine kinase inhibitor (TKI), exhibits potent anticancer activity in EGFR-mutated (mutEGFR) NSCLC patients harboring the T790M gatekeeper mutation [382].